| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| Targets |
EP4 7.6 (pKd)
|
|---|---|
| ln Vitro |
Human middle cerebral (pKb=7.8) and meningeal (pKb=7.6) arteries' PGE2-induced vasodilatation was competitively inhibited by BGC-20-1531 free base, whereas PGE2-induced responses in coronary, pulmonary, or renal arteries were unaffected[1].
|
| ln Vivo |
The dose-dependent inhibition of PGE2-induced increase in canine carotid blood flow is caused by BGC-20-1531 free base (1-10 mg/kg; iv)[1].
|
| Animal Protocol |
Animal/Disease Models: Beagle dogs[1]
Doses: 1- 10 mg/kg Route of Administration: Iv Experimental Results: Caused a dose-dependent antagonism of the PGE2-induced increase in canine carotid blood flow. |
| References |
[1]. Maubach KA, et al. BGC20-1531, a novel, potent and selective prostanoid EP receptor antagonist: a putative new treatment for migraine headache. Br J Pharmacol. 2009;156(2):316-327.
|
| Molecular Formula |
C26H24N2O6S
|
|---|---|
| Molecular Weight |
492.54
|
| CAS # |
736183-35-0
|
| Related CAS # |
BGC-20-1531 hydrochloride;1962928-26-2
|
| SMILES |
S(C1=C([H])C([H])=C([H])C([H])=C1C([H])([H])[H])(N([H])C(C1=C([H])C(C([H])([H])OC2C([H])=C([H])C(C3C([H])=C([H])C(=C([H])N=3)OC([H])([H])[H])=C([H])C=2[H])=C(C([H])([H])[H])O1)=O)(=O)=O
|
| Solubility (In Vitro) |
DMSO: 250 mg/mL (507.57 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.22 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0303 mL | 10.1515 mL | 20.3029 mL | |
| 5 mM | 0.4061 mL | 2.0303 mL | 4.0606 mL | |
| 10 mM | 0.2030 mL | 1.0151 mL | 2.0303 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
